Super-fit mice reveal anti-inflammatory protein that could boost search for Alzheimer’s drugsnews2021-12-10T13:09:29+00:00December 10th, 2021|FierceBiotech|
Moderna, hoping to prove it’s no one-trick COVID pony, posts early peek at mRNA flu shot hopefulnews2021-12-10T12:57:34+00:00December 10th, 2021|FierceBiotech|
Eli Lilly pens $1.5B biobucks pact with China’s Regor for metabolic disease worknews2021-12-10T11:49:30+00:00December 10th, 2021|FierceBiotech|
Roche posts ‘impressive’ TIGIT combo lung cancer data, but trial deaths weigh down sharesnews2021-12-10T10:28:32+00:00December 10th, 2021|FierceBiotech|
Novartis poaches Roche’s neuro and rare disease R&D lead, replacing Shankernews2021-12-10T09:34:13+00:00December 10th, 2021|FierceBiotech|
Albireo CMO Horn is out the door 5 months after US, EU approvals of rare liver disease drugnews2021-12-09T19:02:47+00:00December 9th, 2021|FierceBiotech|
Nanomedicine shrinks vascular lesions in mice and could pave path to new treatmentsnews2021-12-09T17:34:12+00:00December 9th, 2021|FierceBiotech|
Biopharma charts progress in translating CAR-T cell therapies to solid cancersnews2021-12-09T15:20:10+00:00December 9th, 2021|FierceBiotech|
ASH: 2 years in, the survival data on J&J’s rival to Bristol Myers’ BCMA cell therapy are still growingnews2021-12-09T14:25:18+00:00December 9th, 2021|FierceBiotech|
ASH: Novartis posts early clinical data on next-gen CAR-Ts, sets sights on 2022 registration trials news2021-12-09T14:18:45+00:00December 9th, 2021|FierceBiotech|
